Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

OvaSave Study for Crohn’s Disease

October 26, 2011 12:21 pm | News | Comments

TxCell SA announced  final positive results of a Phase 1/2 study in Crohn’s disease (CATS-1) with OvaSave.

TOPICS:

Prosensa Earns Myotonic Dystrophy Research Credit

October 26, 2011 12:16 pm | News | Comments

Prosensa received an innovation credit of up to $6 million from AgentschapNL to support further development of a series of preclinical compounds for the treatment of myotonic dystrophy type 1.

TOPICS:

Wart Compound Shows Promise for Leukemia

October 26, 2011 12:11 pm | News | Comments

A potential leukemia therapy targets only cancer cells, while leaving healthy cells alone.

TOPICS:
Advertisement

PCR Mixture

October 26, 2011 6:47 am | Drug Discovery & Development | Product Releases | Comments

Promega Corporation announced that it has launched GoTaq Long PCR Master Mix, an optimized enzyme mixture for improved long-range PCR; the kit enhances PCR yield, sensitivity, and specificity.

TOPICS:

Drop Plate

October 26, 2011 6:26 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced its µDrop Plate for the quick and easy measurement of samples down to 2 µL. The µDrop Plate provides a straightforward way of analyzing up to 16 microliter-scale samples simultaneously.

TOPICS:

EMD Serono and Fast Forward Commit $3M to MS Research

October 26, 2011 6:14 am | News | Comments

EMD Serono, Inc. and Fast Forward announced a commitment of up to $3 million in 2012 to support innovative early-stage projects directed towards the development of therapies to prevent, treat, or reverse nervous system damage in multiple sclerosis.

TOPICS:

Transdermal Patch Used for Delivery of HIV Drugs

October 26, 2011 5:57 am | News | Comments

An innovative delivery method for human immunodeficiency virus (HIV) medications has been developed through use of a transdermal patch, the first of its kind to treat HIV.

TOPICS:

S*Bio to Begin A Phase 3 Trial of Pacritinib

October 26, 2011 5:52 am | News | Comments

S*BIO Pte Ltd announced plans to initiate a global Phase 3 clinical program of its JAK2 inhibitor pacritinib, to further demonstrate its activity and tolerability for the treatment of myelofibrosis.

TOPICS:
Advertisement

FDA Approves Onfi for Lennox-Gastaut Seizures

October 26, 2011 5:48 am | News | Comments

The U.S. Food and Drug Administration approved Onfi tablets for use as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older.

TOPICS:

Obesity Limits Vaccine Efficacy

October 26, 2011 5:45 am | News | Comments

People carrying extra pounds may need extra protection from influenza. New research shows that obesity may make annual flu shots less effective.

TOPICS:

Merck Income Up 7.5%

October 26, 2011 5:39 am | News | Comments

Pharmaceutical and biotech equipment company Merck said its net income rose 7.5% to $315 million in the third quarter as sales increased for key drugs.

TOPICS:

Lilly Withdraws Xigris Worldwide

October 26, 2011 5:35 am | by Tom Murphy | News | Comments

Drugmaker Eli Lilly and Co. is withdrawing the severe sepsis treatment Xigris from all markets because a recently concluded study showed that it is no longer effective.

TOPICS:

Medtronic Catheter Raises Safety Concerns

October 25, 2011 9:12 am | News | Comments

Federal health regulators say an experimental catheter from Medtronic Inc. that uses extreme heat to correct irregular heartbeats caused safety side effects in nearly one-fifth of patients treated, far exceeding the study's safety goal.

TOPICS:

Cubist Buying Adolor for $190M

October 25, 2011 8:29 am | News | Comments

Cubist Pharmaceuticals, Inc. and Adolor Corporation announced that they have signed a definitive agreement under which Cubist will acquire all of the outstanding shares of Adolor for $4.25 per share in cash, or approximately $190 million.

TOPICS:

ImmunoGen Starts SAR3419 Phase 2 Testing

October 25, 2011 8:25 am | News | Comments

ImmunoGen, Inc. announced that its non-Hodgkin’s lymphoma treatment SAR3419 has started Phase 2 testing. SAR3419 was created by ImmunoGen and licensed to Sanofi preclinically as part of a broader collaboration.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading